title: Future trends in organ transplant recipients--important issues for dermatologists.
abstract: It is on the tip of everyone's tongue in the transplant community that recent improvements in short-term survival of solid organ allografts have not translated into the expected increase in long-term survival. Besides chronic immune-mediated damage to the transplanted organ, the poor long-term survival of allografts has been attributed to the nephrotoxic effects of the calcineurin inhibitors. Moreover, the immunosuppressive burden and metabolic side effects of the current anti-rejection drugs are clearly related to increased rates of malignancies, infections and accelerated atherosclerosis, all of which make up for the premature death of a considerable proportion of transplant recipients with a functioning allograft. Therefore, attempts have been made over the last decade to either reduce or withdraw both steroids and calcineurin inhibitors from maintenance regimens. Furthermore, there is an ongoing intensive search for new less toxic and more specific drugs which would ideally selectively impair the alloimmune response while preserving the immune system's capacity to fight infection and malignancy (i.e. induce tolerance). Moreover, new concepts have emerged to individualize a patient's immunosuppressive therapy based on an improved pretransplant risk assessment. With the causes of chronic allograft damage being increasingly well defined, better and more personalized long-term follow-up strategies are being developed to ultimately prevent late allograft loss. These aspects will be reviewed here with a focus on kidney transplantation and the possible impact of these new approaches on the incidence of skin cancer.
authors.affiliation: Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Petersgraben 4, Basel, Switzerland. daniel.zecher@unibas.ch
authors.forename: Daniel
authors.initials: D
authors.lastname: Zecher
authors.forename: Jürg
authors.initials: J
authors.lastname: Steiger
mesh_terms: D000069594:Abatacept; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D065095:Calcineurin Inhibitors; D005544:Forecasting; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods / Q000639:trends*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016377:Organ Transplantation / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D011719:Pyrazines / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D018570:Risk Assessment / Q000379:methods; D000069283:Rituximab; D012878:Skin Neoplasms / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D065095:Calcineurin Inhibitors; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D011719:Pyrazines; D011993:Recombinant Fusion Proteins; D000069283:Rituximab; D000069286:Bortezomib; C511911:belimumab; D000069594:Abatacept; D000077944:Alefacept